[
  {
    "ts": null,
    "headline": "IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis",
    "summary": "Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=44970c99305296daf18e474dce6d6eac399c35b9ff786a8ac37e272557cbd1fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770356136,
      "headline": "IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis",
      "id": 138373688,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "Clinical research company IQVIA (NYSE: IQV) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $4.36 billion. The company’s full-year revenue guidance of $17.25 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $3.42 per share was 0.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=44970c99305296daf18e474dce6d6eac399c35b9ff786a8ac37e272557cbd1fa"
    }
  }
]